SGP · SpyGlass Pharma Inc. Common Stock
View on chartInsiders & Stakes
| Edward T. Mathers Director | ▲ Buy | Open Market | 6,035,038 Shares held | 2/9/2026 | View profile |
| Yang Rick 10% Owner | ▲ Buy | Open Market | 6,035,038 Shares held | 2/9/2026 | View profile |
| New Enterprise Associates 17, L.P. | ▲ Buy | Open Market | 6,035,038 Shares held | 2/9/2026 | View profile |
| Nielsen Kirk G. Director | ▲ Buy | Open Market | 3,310,619 Shares held | 2/9/2026 | View profile |
| Vensana Capital I GP, LLC | ▲ Buy | Open Market | 3,310,619 Shares held | 2/9/2026 | View profile |
| Pardo Geoffrey B Director | ▲ Buy | Open Market | 2,187,513 Shares held | 2/9/2026 | View profile |
| RA CAPITAL MANAGEMENT, L.P. Director | ▲ Buy | Open Market | 2,054,678 Shares held | 2/9/2026 | View profile |
| Ali Behbahani Director | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| Scott D. Sandell 10% Owner | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| Carmen Chang 10% Owner | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| BASKETT FOREST 10% Owner | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| Makhzoumi Mohamad 10% Owner | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| Florence Anthony A. Jr. 10% Owner | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| Walker Paul Edward 10% Owner | ▼ Sell | Other | 1,357,263 Shares held | 2/9/2026 | View profile |
| Khan Bilal Arshad | ▲ Buy | Open Market | 251,427 Shares held | 2/9/2026 | View profile |
Transaction History
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 2,524,473 | — | 2/9/2026 |
| Edward T. Mathers | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Carmen Chang | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| Vensana Capital I GP, LLC | ▼ Sell | Other | 359,255 | — | 2/9/2026 |
| Vensana Capital I GP, LLC | ▲ Buy | Open Market | 165,000 | $2.6M | 2/9/2026 |
| Ali Behbahani | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Carmen Chang | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Ali Behbahani | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Carmen Chang | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Carmen Chang | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| Edward T. Mathers | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Vensana Capital I GP, LLC | ▼ Sell | Other | 548,067 | — | 2/9/2026 |
| Nielsen Kirk G. | ▼ Sell | Other | 548,067 | — | 2/9/2026 |
| Vensana Capital I GP, LLC | ▼ Sell | Other | 1,690,230 | — | 2/9/2026 |
| Vensana Capital I GP, LLC | ▼ Sell | Other | 548,067 | — | 2/9/2026 |
| Edward T. Mathers | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Nielsen Kirk G. | ▼ Sell | Other | 359,255 | — | 2/9/2026 |
| Ali Behbahani | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Makhzoumi Mohamad | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| Carmen Chang | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Scott D. Sandell | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Edward T. Mathers | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Scott D. Sandell | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Carmen Chang | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▼ Sell | Other | 1,806,644 | — | 2/9/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 3,441,966 | $55.1M | 2/9/2026 |
| RA CAPITAL MANAGEMENT, L.P. | ▲ Buy | Open Market | 248,034 | $4.0M | 2/9/2026 |
| Ali Behbahani | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Nielsen Kirk G. | ▲ Buy | Open Market | 165,000 | $2.6M | 2/9/2026 |
| Nielsen Kirk G. | ▼ Sell | Other | 548,067 | — | 2/9/2026 |
| Scott D. Sandell | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Scott D. Sandell | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Scott D. Sandell | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Scott D. Sandell | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| Scott D. Sandell | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| Carmen Chang | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Ali Behbahani | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Ali Behbahani | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| Ali Behbahani | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Florence Anthony A. Jr. | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| BASKETT FOREST | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| BASKETT FOREST | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| BASKETT FOREST | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| BASKETT FOREST | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| BASKETT FOREST | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| BASKETT FOREST | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| BASKETT FOREST | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| New Enterprise Associates 17, L.P. | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| New Enterprise Associates 17, L.P. | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| New Enterprise Associates 17, L.P. | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| New Enterprise Associates 17, L.P. | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| New Enterprise Associates 17, L.P. | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Yang Rick | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Yang Rick | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Yang Rick | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Yang Rick | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Yang Rick | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Makhzoumi Mohamad | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Makhzoumi Mohamad | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Makhzoumi Mohamad | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Makhzoumi Mohamad | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Makhzoumi Mohamad | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Makhzoumi Mohamad | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| Edward T. Mathers | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Walker Paul Edward | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 |
| Walker Paul Edward | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Walker Paul Edward | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 |
| Walker Paul Edward | ▼ Sell | Other | 737,962 | — | 2/9/2026 |
| Walker Paul Edward | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 |
| Walker Paul Edward | ▼ Sell | Other | 954,990 | — | 2/9/2026 |
| Walker Paul Edward | ▼ Sell | Other | 402,273 | — | 2/9/2026 |
| Pardo Geoffrey B | ▼ Sell | Other | 1,875,013 | $0 | 2/9/2026 |
| Pardo Geoffrey B | ▲ Buy | Open Market | 312,500 | $5.0M | 2/9/2026 |
| Khan Bilal Arshad | ▲ Buy | Open Market | 20,000 | $320K | 2/9/2026 |
| Khan Bilal Arshad | ▲ Buy | Open Market | 115,000 | $1.8M | 2/9/2026 |
| Nielsen Kirk G. | ▼ Sell | Other | 1,690,230 | — | 2/9/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
SpyGlass Pharma Schedules Upcoming Investor Conference Participation
SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.
SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.